---
title: "Liver-Pancreas Fat Deposition: Impact on Cardiometabolic Multimorbidity and Cardiac Dysfunction."
description: "Metabolic dysfunction-associated steatotic liver disease (MASLD) and pancreatic steatosis (PS) are interconnected ectopic fat conditions linked to cardiometabolic dysregulation. Their combined effect on the long-term risk o..."
date: "2026-03-01"
category: "ia-radiologia"
pubmedId: "41689358"
author: "Li-You Lian, Tianyi Xia, Zhong-Wei Chen et al."
tags: ["cardiac magnetic resonance", "cardiometabolic multimorbidity", "metabolic dysfunction&#x2010;associated steatotic liver disease", "pancreatic steatosis", "proton density fat fraction"]
---

## Resumen

**BACKGROUND &amp; AIMS:** Metabolic dysfunction-associated steatotic liver disease (MASLD) and pancreatic steatosis (PS) are interconnected ectopic fat conditions linked to cardiometabolic dysregulation. Their combined effect on the long-term risk of cardiometabolic multimorbidity (CMM; &#x2265;&#x2009;2 of diabetes, hypertension, coronary heart disease, and stroke) and cardiac remodelling remains unclear. **METHODS:** We examined cross-sectional associations between PS and the severity of MASLD histology in a biopsy-proven MASLD cohort from China. Subsequently, using the UK Biobank, we assessed the long-term risk of developing both incident CMM and cardiac structural/functional alterations (via cardiac magnetic resonance [CMR]) associated with single-organ versus dual-organ steatosis. Exploratory proteomic profiling was performed to identify potential molecular pathways. **RESULTS:** In the biopsy-proven cohort (n&#x2009;=&#x2009;482), both continuous pancreatic proton density fat fraction and PS status were associated with severe hepatic steatosis, lobular inflammation, and fibrosis (all p&#x2009;&lt;&#x2009;0.05). In the UK Biobank cohort (n&#x2009;=&#x2009;16&#x2009;408; median follow-up of 5.6&#x2009;years), the coexistence of MASLD and PS additively increased the risk of new-onset CMM (HR&#x2009;=&#x2009;2.013, 95% CI: 1.219-3.322, p&#x2009;=&#x2009;0.006). Dual-organ steatosis was also associated with marked cardiac alterations, specifically increased left ventricular mass and impaired ventricular function. Proteomics revealed upregulation of lysosomal catabolic and glycosaminoglycan-degrading pathways in dual-organ steatosis compared to single-organ steatosis. Gene Ontology highlighted heparan sulphate proteoglycan catabolism as a hallmark of dual-organ involvement. **CONCLUSION:** PS is associated with greater severity of MASLD histology, and the concomitant involvement of both the liver and pancreas drives a higher risk of CMM and cardiac remodelling.

## Información del artículo

- **Revista:** Liver international : official journal of the International Association for the Study of the Liver
- **Fecha de publicación:** 2026-03-01
- **Autores:** Li-You Lian, Tianyi Xia, Zhong-Wei Chen, Cai-Yun Wen, Xiao-Dong Zhou
- **DOI:** [10.1111/liv.70548](https://doi.org/10.1111/liv.70548)
- **PubMed ID:** [41689358](https://pubmed.ncbi.nlm.nih.gov/41689358/)

## Referencias

Este artículo fue obtenido automáticamente desde [PubMed](https://pubmed.ncbi.nlm.nih.gov/41689358/), la base de datos de literatura biomédica del National Center for Biotechnology Information (NCBI).
